The Pharma & Biotech team at Citigate Dewe Rogerson, the leading international consultancy specialising in financial and corporate communications, is pleased to provide an update of team and client activities during the second quarter of 2010.

During this period, the team has been working on a wide range of client activities, a highlight of which was hosting a very successful Capital Markets Day for Algeta, the cancer company developing Alpharadin for bone metastases, at our offices in London. The event featured a talk by Dr Chris Parker from the UK Institute of Cancer Research and Royal Marsden Hospital, on the landscape of prostate cancer therapies and where new treatments including Alpharadin will likely fit in. Dr Parker is the Principal Investigator of Algeta's phase III clinical trial with Alpharadin. The event attracted more than 30 members of the UK life sciences investment community and international press.

Continuing this theme, the Citigate team hosted a "City Lunch" meeting on behalf of Clavis Pharma, to brief an invited audience from the investment community and press on its novel treatments to improve the efficacy of first-line cancer therapies, cytarabine and gemcitabine. In addition to Clavis' CEO, speakers at the lunch included Professor Francis Giles, Chief of Hematology and Medical Oncology at The University of Texas Health Science Center, and Patrick Mahaffy, CEO of Clovis Oncology, Clavis' development partner for CP-4126, which is in Phase II trials for pancreatic cancer.

Further activities of the Citigate team's clients can be found below.

Finally, in team news, we are very pleased to welcome Malcolm Robertson as Account Manager. Malcolm has over seven years experience working in the biotechnology and clean technology sectors. Prior to joining Citigate, he worked as a cleantech analyst at VB/Research and before this as at TVF Communications providing communications support to healthcare and pharmaceutical companies. Malcolm has a degree and PhD in Biochemistry from the University of Oxford. He will be providing support on existing Pharma & Biotech clients and will also be looking to broaden the team's offering into the cleantech space.

New Clients
	Archimedes Pharma is a dynamic growing international specialty pharmaceutical company with an established commercial organisation in the UK and Europe and a portfolio of products marketed to specialist prescribers. The Company's lead product, PecFent®, an innovative fentanyl nasal spray being developed for breakthrough cancer pain, is on the verge of being approved in Europe and Citigate was brought in to support this milestone achievement.
	Reinnervate is an innovative life sciences company dedicated to making routine 3D cell culture a reality for researchers in academia and in the pharmaceutical and related industries. Citigate was appointed to provide broad communications support to raise the profile of the Company ahead of the launch of its novel 3D cell culture platform, Alvetex.
	Stentys is pioneering the development of innovative stents to treat blocked arteries. Citigate teams in London and Paris are working with the company to raise its profile and awareness of its novel, self-expanding, CE-marked stent. The Stentys stent is now in clinical trials comparing its use to existing balloon-expanded stents for the treatment of patients who have experienced an acute myocardial infarction.
Portfolio Company News (click links for further details) Financial News Protek IPO in Russia raises US$ 400 million Abingworth takes major stake in Epigenomics in EUR 33 million capital increase Abingworth commits US$ 40 million to support recapitalisation and growth of Secure EDI Biocartis raises EUR 30 million in Series B financing round Corporate and Business Development Abingworth wins Venture House of the Year in the BVCA/Real Deals Private Equity Awards Clavis Pharma's partner for CP-4126, Clovis Oncology signs agreement to develop and commercialize hENT1 companion diagnostic with Ventana Medical Systems Clavis Pharma licenses rights to hENT1 antibody to Ventana Medical Systems immatics enters collaboration with the US National Cancer Institute to advance the development of IMA950 for glioblastoma ThromboGenics and BioInvent receive EUR 10 million milestone payment from Roche as TB-403 anti-cancer antibody begins new clinical study Product Development Algeta boosts patient numbers in ALSYMPCA Phase III trial Archimedes Pharma receives CHMP positive opinion for PecFent® for the treatment of breakthrough cancer pain immatics presents positive Phase II results with its therapeutic cancer vaccine IMA901, in patients with advanced kidney cancer at ASCO Kuros completes patient recruitment in a Phase IIb trial of KUR-113 in patients with tibial shaft fractures Movetis starts Phase III clinical trial with prucalopride (Resolor) in patients with opioid-induced constipation Stentys completes enrollment in clinical study of its breakthrough stent to treat acute myocardial infarction ThromboGenics' microplasmin meets primary endpoint in Phase III trial for the non-surgical treatment of symptomatic vitreomacular adhesion ThromboGenics and BioInvent announce positive topline results from Phase II study with anti-Factor VIII (TB-402) for the prophylaxis of venous thromboembolism People and Appointments Algeta elects Judith Hemberger and Kapil Dhingra to its board of directors Clavis Pharma appoints Anders P. Wiklund and Annette V. Clancy to its board of directors Clavis Pharma appoints Athos Gianella-Borradori, MD as Chief Medical Officer Vantia Therapeutics appoints Andrew Crockett as Chief Executive Officer